Essential Premium

RA Capital Doubles Down on Private Deals as Year-End Frenzy Builds

The biopharma specialist hedge fund is on track for its busiest quarter yet, pouring money into startups while launching a new vehicle focused on planetary health.

Third Point Inches Lower in November as Magnificent Seven Stumble

Dan Loeb’s multistrategy fund saw only a slight dip last month, but the drivers behind the loss give a glimpse of its positioning heading into year-end.

Sponsored

Morningstar’s Idzorek Explores a New Paradigm for Allocators

Greenlight Builds Momentum After Summer Losses

David Einhorn’s hedge fund posts a gain in November, extending a three-month rally that has lifted returns for the year.

Related Content

How Third Point Fared After Increasing Bets on Stocks

Stephen Taub

Why CalSTRS and Family Offices Love This Life Sciences VC Firm

Michael Thrasher

A Jim Simons Market Mystery — Solved?

Richard Teitelbaum

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram